Diclofenac sodium, a benzene-acetic acid derivative, is a nonsteroidal anti-inflammatory drug (NSAID) ,has analgesic, anti-inflammatory, and antipyretic properties.

US authorities greenlight a combined treatment of TAGRISSO® (osimertinib) and chemotherapy for individuals battling advanced lung cancer with EGFR mutations.

Datopotamab deruxtecan (Dato-DXd) is an ADC comprising a humanized anti-TROP2 IgG1 monoclonal antibody bonded to a potent topoisomerase I inhibitor through a stable, tumor-specific, cleavable tetrapeptide linker.

U.S. Authorities Approve Review for Deruxtecan-Datopotamab Treatment Submission for Earlier Managed Advanced Non-Squamous NSCLC Cases.

Tadalafil, sold as Cialis, is a PDE5 inhibitor, similar to sildenafil (Viagra) and vardenafil (Levitra).

Almirall gains rights to develop Novo Nordisk’s anti-IL-21 antibody for dermatologic applications as a pioneering treatment.

Early PSA response correlates with better outcomes in mHSPC patients receiving ADT and ARPIs.

Citius Pharma re-submits its LYMPHIR™ BLA, comprising Denileukin Diftitox, aiming to treat relapsed/refractory Cutaneous T-Cell Lymphoma in adults.

Mupirocin (BACTROBAN) is an antibiotic that blocks RNA synthetase and treats impetigo from Staph aureus and Streptococcus pyogenes when applied to the skin.

Kurome Therapeutics has received authorization from the FDA to conduct clinical trials for KME-0584, aimed at addressing Acute Myeloid Leukemia (AML) and advanced-stage Myelodysplastic Syndromes (MDS).

Quetiapine, marketed as SEROQUEL, is an atypical antipsychotic medication developed and produced by AstraZeneca.

Acousia Therapeutics disclosed that it has initiated participant enrollment for its second stage PROHEAR trial.